The inactivation of MEN1 is often biallelic (in 40% of cases [30]) and somatic or germline point mutations in the gene are coupled with loss of heterozygosity (LoH) at the MEN1 alleles in tumor tissue. This evidence concerns the gene MEN1 and neoplasm.